# Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia

> **NCT01350999** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 503 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** omega-3-acid ethyl esters 90 (TAK-085)
- **DRUG:** Eicosapentaenoic acid-ethyl (EPA)

## Key facts

- **NCT ID:** NCT01350999
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01350999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01350999, "Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT01350999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*